$619 Million is the total value of KPCB XIII Associates, LLC's 4 reported holdings in Q4 2020. The portfolio turnover from Q3 2020 to Q4 2020 was - .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| PGNY | New | Progyny, Inc. | $470,262,000 | – | 11,093,696 | +100.0% | 76.02% | – |
| LUNG | New | Pulmonx Corporation | $88,294,000 | – | 1,421,386 | +100.0% | 14.27% | – |
| EPZM | New | Epizyme, Inc. | $41,682,000 | – | 3,838,166 | +100.0% | 6.74% | – |
| TMDX | New | TransMedics Group, Inc. | $18,372,000 | – | 932,221 | +100.0% | 2.97% | – |
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2021-02-16
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| Progyny, Inc. | 8 | Q3 2023 | 96.0% |
| Pulmonx Corporation | 8 | Q3 2023 | 14.3% |
| Epizyme, Inc. | 4 | Q3 2021 | 6.9% |
| TransMedics Group, Inc. | 4 | Q3 2021 | 7.9% |
| Movella Holdings Inc. | 3 | Q3 2023 | 4.9% |
| Rapid Micro Biosystems, Inc. | 1 | Q3 2021 | 0.1% |
View KPCB XIII Associates, LLC's complete holdings history.
Latest filings
| Type | Filed |
|---|---|
| 13F-HR | 2023-11-08 |
| 13F-HR | 2023-08-08 |
| 13F-HR | 2023-05-12 |
| 3 | 2023-02-17 |
| 13F-HR | 2023-02-07 |
| 13F-HR | 2021-10-25 |
| 13F-HR | 2021-07-28 |
| 4 | 2021-06-22 |
| 13F-HR | 2021-05-13 |
| 4 | 2021-04-19 |
View KPCB XIII Associates, LLC's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.